Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection

Journal of Virology

Volumn 83, Issue 14, 2009, Pages 7176-7184

  Wyatt, Linda S ^a   Earl, Patricia L ^a   Xiao, Wei ^a   Americo, Jeffrey L ^a   Cotter, Catherine A ^a   Vogt, Jennifer ^a   Moss, Bernard ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; VIRUS ENVELOPE PROTEIN;

ARTICLE; CODON; CYTOPLASM; FRAMESHIFT MUTATION; GENE DELETION; GENE EXPRESSION; GENETIC CODE; GENETIC CONSERVATION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECOMBINANT GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS MUTATION; STRUCTURAL GENE; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

BASE SEQUENCE; CELLS, CULTURED; FUSION PROTEINS, GAG-POL; GENE EXPRESSION; GENETIC VECTORS; HIV; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECOMBINATION, GENETIC; SELECTION (GENETICS); VACCINIA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS;

EID: 67650424327     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00687-09     Document Type: Article

References (37)

1. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 2006. Corrigendum to "The complete genomic sequence of the modified vaccinia Ankara (MVA) strain: comparison with other orthopoxviruses." Virology 350:501-502. [Correction to 244:365, 1998.]
2. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
3. Caras, I. W., G. N. Weddell, M. A. Davitz, V. Nussenzweig, and D. W. Martin, Jr. 1987. Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science 238:1280-1283.
4. Challberg, M. D., and P. T. Englund. 1979. Purification and properties of the deoxyribonucleic acid polymerase induced by vaccinia virus. J. Biol. Chem. 254:7812-7819.
5. Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. 1992. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-celltropic isolates: definition of critical amino acids involved in cell tropism. J. Virol. 66:6547-6554.
6. Citarella, R. V., R. Muller, A. Schlabach, and A. Weissbach. 1972. Studies on vaccinia virus-directed deoxyribonucleic acid polymerase. J. Virol. 10:721-729.
7. Earl, P. L., C. C. Broder, R. W. Doms, and B. Moss. 1997. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol. 71:2674-2684.
8. Earl, P. L., C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. 1994. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68:3015-3026.
9. Earl, P. L., A. W. Hügin, and B. Moss. 1990. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64:2448-2451.
10. Earl, P. L., B. Moss, L. S. Wyatt, and M. W. Carroll. 1998. Generation of recombinant vaccinia viruses, p. 16.17.1-16.17.19. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 2. Greene Publishing Associates, Wiley Interscience, New York, NY.
11. Ellenberger, D., L. Wyatt, B. Li, S. Buge, N. Lanier, I. V. Rodriguez, C. A. Sariol, M. Martinez, M. Monsour, J. Vogt, J. Smith, R. Otten, D. Montefiori, E. Kraiselburd, B. Moss, H. Robinson, J. McNicholl, and S. Butera. 2005. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02-AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 340:21-32.
12. Ellenberger, D. L., B. Li, L. D. Lupo, S. M. Owen, J. Nkengasong, M. S. Kadio-Morokro, J. Smith, H. Robinson, M. Ackers, A. Greenberg, T. Folks, and S. Butera. 2002. Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 302:155-163.
13. Gomez, C. E., J. L. Najera, M. Krupa, and M. Esteban. 2008. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8:97-120.
14. Kozak, M. 1992. Regulation of translation in eukaryotic systems. Annu. Rev. Cell Biol. 8:197-225.
15. Kunkel, T. A., and K. Bebenek. 2000. DNA replication fidelity. Annu. Rev. Biochem. 69:497-529.
16. Leitner, T., B. Foley, B. H. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and B. Korber (ed.). 2003. HIV Sequence Compendium. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
17. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. 1975. Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA. Infection 3:6-14. (In German.)
18. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
19. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA 93:11341-11348.
20. Moss, B., and F. De Silva. 2006. Poxvirus DNA replication and human disease, p. 707-727. In M. L. DePamphilis (ed.), DNA replication and human disease. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
21. Moss, B., G. L. Smith, J. L. Gerin, and R. H. Purcell. 1984. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311:67-69.
22. Paoletti, E., B. R. Lipinskas, C. Samsonoff, S. R. Mercer, and D. Panicali. 1984. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc. Natl. Acad. Sci. USA 81:193-197.
23. Parks, R. J., C. Winchcombe-Forhan, A. M. DeLange, X. Xing, and D. H. Evans. 1998. DNA ligase gene disruptions can depress viral growth and replication in poxvirus-infected cells. Virus Res. 56:135-147.
24. Rempel, R. E., and P. Traktman. 1992. Vaccinia virus-B1 kinase: phenotypic analysis of temperature-sensitive mutants and enzymatic characterization of recombinant proteins. J. Virol. 66:4413-4426.
25. Smith, J. M., R. R. Amara, H. M. McClure, M. Patel, S. Sharma, H. Yi, L. Chennareddi, J. G. Herndon, S. T. Butera, W. Heneine, D. L. Ellenberger, B. Parekh, P. L. Earl, L. S. Wyatt, B. Moss, and H. L. Robinson. 2004. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in macaques. AIDS Res. Hum. Retrovir. 20:654-665.
26. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schäfer, and A. Holzner. 1974. MVA vaccination against smallpox: clinical trials of an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wschr. 99:2386-2392. (In German.)
27. Stittelaar, K. J., T. Kuiken, R. L. de Swart, G. van Amerongen, H. W. Vos, H. G. Niesters, P. van Schalkwijk, T. van der Kwast, L. S. Wyatt, B. Moss, and A. D. Osterhaus. 2001. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700-3709.
28. Stittelaar, K. J., L. S. Wyatt, R. L. de Swart, H. W. Vos, J. Groen, G. van Amerongen, R. S. van Binnendijk, S. Rozenblatt, B. Moss, and A. Osterhaus. 2000. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74:4236-4243.
29. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
30. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennink, and B. Moss. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032-1040.
31. Toohey, K., K. Wehrly, J. Nishio, S. Perryman, and B. Chesebro. 1995. Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology 213: 70-79.
32. Weisberg, R. A., and S. Adhya. 1977. Illegitimate recombination in bacteria and bacteriophage. Annu. Rev. Genet. 11:451-473.
33. Welihinda, A. A., W. Tirasophon, and R. J. Kaufman. 1999. The cellular response to protein misfolding in the endoplasmic reticulum. Gene Expr. 7:293-300.
34. Wyatt, L. S., I. M. Belyakov, P. L. Earl, J. A. Berzofsky, and B. Moss. 2008. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 372:260-272.
35. Wyatt, L. S., P. L. Earl, L. A. Eller, and B. Moss. 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101:4590-4595.
36. Wyatt, L. S., P. L. Earl, J. Vogt, L. A. Eller, D. Chandran, J. Liu, H. L. Robinson, and B. Moss. 2008. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26:486-493.
37. Wyatt, L. S., S. T. Shors, B. R. Murphy, and B. Moss. 1996. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451-1458.